TEVA:NYE-Teva Pharmaceutical Industries Limited American Depositary Shares (USD)

EQUITY | Drug Manufacturers - Specialty & Generic | New York Stock Exchange

Last Closing

USD 18.87

Change

0.00 (0.00)%

Market Cap

USD 38.25B

Volume

0.01B

Analyst Target

USD 12.19
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Teva Pharmaceutical Industries Ltd develops, produces and markets generic, branded & OTC medicines. Its products include Copaxone, Azilect and Provigil.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-08-31 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
ZTS Zoetis Inc

+0.38 (+0.20%)

USD 83.17B
TAK Takeda Pharmaceutical Co Ltd A..

-0.12 (-0.81%)

USD 47.69B
HLN Haleon plc

+0.13 (+1.25%)

USD 47.33B
RDY Dr. Reddy’s Laboratories Ltd..

+0.12 (+0.15%)

USD 13.37B
CTLT Catalent Inc

-0.07 (-0.12%)

USD 10.83B
ELAN Elanco Animal Health

+0.08 (+0.56%)

USD 7.59B
AMRX Amneal Pharmaceuticals, Inc. C..

+0.15 (+1.77%)

USD 2.67B
BHC Bausch Health Companies Inc

+0.02 (+0.32%)

USD 2.32B
CPHI China Pharma Holdings Inc

N/A

USD 3.04M
YCBD cbdMD Inc

-0.02 (-3.58%)

USD 2.14M

ETFs Containing TEVA

ISRA VanEck Israel ETF 10.18 % 0.60 %

+0.32 (+0.48%)

USD 0.07B
FLWR:SW 5.80 % 0.00 %

N/A

N/A
ISRPF iShares Public Limited Co.. 5.39 % 0.00 %

N/A

USD 2.22B
IDVO Amplify International Enh.. 3.08 % 0.00 %

+0.14 (+0.48%)

USD 0.10B
ALFI 0.00 % 0.88 %

N/A

N/A
EIS iShares MSCI Israel ETF 0.00 % 0.59 %

+0.45 (+0.48%)

N/A
GNRX 0.00 % 0.55 %

N/A

N/A
GWL 0.00 % 0.34 %

N/A

N/A
ISRL:LSE 0.00 % 0.00 %

N/A

N/A
TASE:LSE 0.00 % 0.00 %

N/A

N/A
IS3T:F iShares IV Public Limited.. 0.00 % 0.00 %

+0.25 (+0.48%)

N/A
ISRCF iShares V Public Limited .. 0.00 % 0.00 %

N/A

N/A
ISRHF iShares V Public Limited .. 0.00 % 0.00 %

+0.04 (+0.48%)

N/A
ISRUF iShares V Public Limited .. 0.00 % 0.00 %

N/A

N/A
ISRZF iShares II Public Limited.. 0.00 % 0.00 %

N/A

N/A
ISRIF 0.00 % 0.00 %

N/A

N/A
ISRVF 0.00 % 0.00 %

N/A

N/A
ISRWF iShares II Public Limited.. 0.00 % 0.00 %

N/A

N/A
ISRNF 0.00 % 0.00 %

N/A

N/A
ISRRF 0.00 % 0.00 %

N/A

N/A
FLWG:LSE 0.00 % 0.00 %

N/A

N/A
FLWR:LSE 0.00 % 0.00 %

N/A

N/A
BLUM:XETRA 0.00 % 0.00 %

N/A

N/A
BLUM:F 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -77.41% 7% C- 3% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -77.41% 7% C- 3% F
Trailing 12 Months  
Capital Gain -76.03% 7% C- 4% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -76.03% 7% C- 4% F
Trailing 5 Years  
Capital Gain -65.82% 29% F 8% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return -65.82% 29% F 8% B-
Average Annual (5 Year Horizon)  
Capital Gain 9.66% N/A N/A 68% D+
Dividend Return 9.66% N/A N/A 62% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 35.33% N/A N/A 28% F
Risk Adjusted Return 27.34% N/A N/A 47% F
Market Capitalization 38.25B N/A N/A N/A N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 22.40 N/A N/A
Price/Book Ratio N/A N/A N/A
Price / Cash Flow Ratio N/A N/A N/A
Price/Free Cash Flow Ratio N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A
Return on Invested Capital N/A N/A N/A
Return on Assets N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector